International Board of Directors Election

Meet the 2021-2022 Board

The ISPE International Board of Directors 2021 Election has concluded and the results are in. Below is the list of those Members who have been elected to serve on the 2021-2022 Board of Directors.

The leadership transition between the 2020 - 2021 Board and the 2021 - 2022 Board will take place during the 2021 ISPE Annual Meeting & Expo on Tuesday, 2 November.


Jörg Zimmermann
Vice President, Vetter Development Service, External Affairs
Vetter Pharma-Fertigung GmbH & Co.
Michael L. Rutherford
Executive Director, Computer Systems Quality & Data Integrity
Syneos Health
Vice Chair
Scott W. Billman
Global Head of Engineering
Jeffrey A. Biskup, PE
CEO and Chairman of the Board
Joanne R. Barrick, RPh
Advisor, Global Validation
Eli Lilly and Company
Past Chair

Re-elected Directors

Ylva Ek
Chief Quality Officer (CQO)
KeyPlants AB
Lou W. Kennedy
CEO and Owner
Nephron Pharmaceuticals

New Directors

Georg Singewald, PhD
VP, Head of Global Quality Control
Genentech, A Member of the Roche Group
Timothy J.N. Watson, PhD
Executive Director & Team Leader, CMC Advisory Office
Pfizer Inc

Board Members Continuing a Term in 2021-2022

The following individuals will be continuing a two-year term in 2021-2022.

Vivianne J. Arencibia
Independent Consultant
Arencibia Quality Compliance Associates
Nina S. Cauchon, PhD
Director Regulatory Affairs - CMC
Amgen Inc.
Chris Chen, PhD
WuXi Biologics (Shanghai) Co., Ltd.
David Doleski
Compliance Head for Biologics Quality Operations
Teresa Minero
Founder & CEO
LifeBee - Digitalizing Life Sciences
Hirofumi Suzuki, PhD
Product Supply Japan, Head of Product Supply Coordination
Bayer Yakuhin Ltd

Board Members Completing Their Service

The following individuals will complete their Board service and will officially end their term at the 2021 ISPE Annual Meeting. ISPE thanks these individuals for their dedication and commitment to the organization.

Frances M. Zipp
President & CEO
Lachman Consultant Services
Stephen Mahoney
Executive Director, Global Quality & Compliance
Genentech, A Member of the Roche Group
Alice Redmond, PhD
Chief Strategy Officer

Candidate Nomination and Selection Process

Below are the steps taken for selecting candidates to be on the ballot:

  • Each year, the global membership of ISPE are asked to provide the names of potential candidates to the ISPE Nominating Committee. Candidates are proposed on the basis of a number of considerations communicated in the call for nominations including: strategic thinking, leadership skills, “business sense,” knowledge of the global pharma / biopharma industry, and the ability to commit the time and resources required to actively participate on the Board.
  • The Nominating Committee proposes a list of potential candidates for the vacancies on the Executive Committee and the International Board of Directors. The Board approves this list before the election.
  • Approved candidates are asked to confirm their willingness to stand for the election and to demonstrate that they have the support of their employer to serve.
  • Following the receipt of this information, the balloting process is arranged using an independent outside body, Intelliscan, Inc.

Intelliscan, Inc. conducts the entire election process and reports the results to the International Board of Directors.